Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy
- 1 August 2001
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 91 (2), 149-166
- https://doi.org/10.1016/s0163-7258(01)00153-x
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- DEPOSITION OF PG-M/VERSICAN IS A MAJOR CAUSE OF HUMAN CORONARY RESTENOSIS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTYThe Journal of Pathology, 1996
- Increased extracellular matrix synthesis by smooth-muscle cells obtained from in vivo restenotic lesions by directional coronary atherectomyAmerican Heart Journal, 1996
- Restenosis: The cost to societyAmerican Heart Journal, 1995
- Histololfic analysis of directional coronary atherectomy samples: A review of findings and their clinical relevanceThe American Journal of Cardiology, 1993
- Effects of diltiazem on complications and restenosis after coronary angioplastyThe American Journal of Cardiology, 1991
- Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplastyAmerican Heart Journal, 1989
- Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplastyAmerican Heart Journal, 1989
- Aspirin and Dipyridamole in the Prevention of Re-Stenosis after Percutaneous Transluminal Coronary AngioplastyNew England Journal of Medicine, 1988
- Compensatory Enlargement of Human Atherosclerotic Coronary ArteriesNew England Journal of Medicine, 1987
- Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the national heart, lung, and blood instituteThe American Journal of Cardiology, 1984